EMPAGLIFLOZIN USE AND THE RISK OF NEPHROLITHIASIS IN PATIENTS WITH TYPE 2 DIABETES

被引：0
|
作者：
Tang, Francesca [1 ]
Paik, Julie [2 ,3 ]
Tesfaye, Helen [2 ,3 ]
Zakoul, Heidi [2 ,3 ]
Schmedt, Niklas [5 ]
Koeneman, Lisette [6 ]
Seman, Leo [7 ]
Curhan, Gary C. [2 ,3 ]
Wexler, Deborah J. [3 ,4 ]
Patorno, Elisabetta [2 ,3 ]
机构：
[1] Boehringer Ingelheim Pty Ltd, N Ryde, Australia
[2] Brigham & Womens Hosp, Boston, MA USA
[3] Harvard Med Sch, Boston, MA USA
[4] Massachusetts Gen Hosp, Boston, MA USA
[5] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
[6] Lilly Deutschland GmbH, Bad Homburg, Germany
[7] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT USA
来源：
NEPHROLOGY | 2023年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：29 / 29
页数：1
相关论文
共 50 条
  • [1] Empagliflozin Use and the Risk of Nephrolithiasis in Patients With Type 2 Diabetes
    Paik, Julie M.
    Tesfaye, Helen
    Zakoul, Heidi
    Schmedt, Niklas
    Koeneman, Lisette
    Seman, Leo
    Curhan, Gary C.
    Wexler, Deborah J.
    Patorno, Elisabetta
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 673 - 673
  • [2] Empagliflozin and the Risk of Retinopathy in Patients With Type 2 Diabetes
    Tesfaye, Helen
    Paik, Julie M.
    Roh, Miin
    Htoo, Phyo T.
    Zakoul, Heidi
    Schmedt, Niklas
    Koeneman, Lisette
    Wexler, Deborah J.
    Patorno, Elisabetta
    JAMA OPHTHALMOLOGY, 2025, 143 (01) : 62 - 71
  • [3] Empagliflozin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
    Scott, Lesley J.
    DRUGS, 2014, 74 (15) : 1769 - 1784
  • [4] Empagliflozin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
    Lesley J. Scott
    Drugs, 2014, 74 : 1769 - 1784
  • [5] Erratum to: Empagliflozin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
    Lesley J. Scott
    Drugs, 2015, 75 : 141 - 141
  • [6] Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes
    Kohler, Sven
    Salsali, Afshin
    Hantel, Stefan
    Kaspers, Stefan
    Woerle, Hans J.
    Kim, Gabriel
    Broedl, Uli C.
    CLINICAL THERAPEUTICS, 2016, 38 (06) : 1299 - 1313
  • [7] Safety and tolerability of empagliflozin in patients with Type 2 diabetes
    Salsali, A.
    Kohler, S.
    Hantel, S.
    Kim, G.
    Woerle, H. J.
    Broedl, U. C.
    DIABETIC MEDICINE, 2016, 33 : 66 - 66
  • [8] Sodium-Glucose Cotransporter 2 Inhibitors and Nephrolithiasis Risk in Patients With Type 2 Diabetes
    Paik, Julie M.
    Tesfaye, Helen
    Curhan, Gary C.
    Zakoul, Heidi
    Wexler, Deborah J.
    Patorno, Elisabetta
    JAMA INTERNAL MEDICINE, 2024, 184 (03) : 265 - 274
  • [9] Empagliflozin on the risk of retinopathy in patients with type 2 diabetes: Results from the EMPRISE study
    Tesfaye, Helen
    Htoo, Phyo Than T.
    Paik, Julie M.
    Zakoul, Heidi
    Schmedt, Niklas
    Deruaz-Luyet, Anouk
    Koeneman, Lisette
    Wexler, Deborah
    Patorno, Elisabetta
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 15 - 15
  • [10] Cost-utility of empagliflozin in patients with type 2 diabetes at high cardiovascular risk
    Nguyen, Elaine
    Coleman, Craig I.
    Nair, Suresh
    Weeda, Erin R.
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2018, 32 (02) : 210 - 215
12345